Application

Anti-Synaptophysin, clone 2B21 ZooMAb, Cat. No. ZRB1365, a recombinant Rabbit monoclonal antibody that targets Synaptophysin and is tested in Immunocytochemistry, and Immunohistochemistry (Paraffin), and Western Blotting.

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected Synaptophysin in rat brain tissue lysate.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected Synaptophysin in rat brain tissue sections.Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected Synaptophysin in PC12 cells.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

GST/His-tagged recombinant fragment corresponding to 86 amino acids from the C-terminal region of rat Synaptophysin.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

30 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 2B21 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects Synaptophysin. It targets an epitope within 86 amino acids from the C-terminal region. It does not react with human Synaptophysin.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

Synaptophysin (UniProt: P07825; also known as Major synaptic vesicle protein p38) is encoded by the Syp gene (Gene ID: 24804) in rat. Synaptophysin belongs to the synaptophysin/synaptobrevin family of proteins. It is one of the major glycoproteins present in presynaptic vesicles and in various neuroendocrine cells of both neuronal and epithelial phenotype. Its structure consists of a hexameric protein of four transmembrane spans with a short cytoplasmic amino- and a long carboxy-terminal tail. Both amino- and carboxy-terminals are exposed on the cytoplasmic surface of the synaptic vesicle membrane. The C-terminal domain of Synaptophysin is required for endocytosis during, but not after, cessation of sustained synaptic transmission. Synaptophysin is involved in organizing membrane components and may regulate endocytosis to ensure vesicle availability following sustained neuronal activity. It is also involved in the regulation of short-term and long-term synaptic plasticity. Syp/neurons display functional deficiencies and slower recovery of the recycling synaptic vesicle pool. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Kwon, SE., and Chapman, ER (2011). Neuron. 70(5); 847- 854).